Online ISSN: 2515-8260

Keywords : Rheumatoid arthritis


Sevara Mukhammadieva; Elnora Djuraeva; Nargiza Abduazizova

European Journal of Molecular & Clinical Medicine, 2020, Volume 7, Issue 2, Pages 2439-2449

patients under 30. The control group consisted of 110 healthy middle-aged
individuals. In the surveyed population, those with 1 to 5 years of age were the largest group
(38.3%), followed by those with 5 to 10 years of age (34%). In 66.3% of the patients of RA MT
was used as a base preparation. The average dose (median) of MT over the study period was
10 mg per week. 80% of patients took prednisolone in an average dose of 10 mg/day. The
content of lipids in venous blood was determined by photocolometry on Vitros SYSTEM
Chemistry DT 60 biochemical analyzer (Austria). Results: RA patients who took MT showed a
significant increase in the level of triglycerides (TG). Also, it is characterised by an increase
in TG levels and a decrease in the concentration of high-density lipoprotein cholesterol
(HDL) and an increase in the atherogenicity factor. A more pronounced decrease in HDL
levels. Significantly high indicators of the atherogenicity coefficient, which to a lesser extent
depended on the duration of MT use. Low-density lipoprotein cholesterol (LDL) and
triglyceridemia are also proved to be serious risk factors for atherosclerosis and
cardiovascular heart diseases (CHD). Also according to the results of the research, special
attention is paid to the use of hypolipidemic drugs, which is promising in improving the
prognosis and reducing cardiovascular injuries in RA patients. In the group of patients who
received additional lipidex SR, there was a decrease in the level of OHS by 17.1%, an
important shift was observed on the part of TG, this indicator decreased by 29.7% and
practically did not differ from the control indicators. HDL cholesterol in the SR lipidex group
increased significantly by 37.7%. These fibrates have a stimulating effect on all components of

Type of article: Review article Title of the article: SJOGREN’S SYNDROME IN DENTIST PERSPECTIVE- A REVIEW

Dr. G. Nishanth; Dr. N. Anitha; Dr. N. Aravindha Babu; Dr. K.M.K. Masthan

European Journal of Molecular & Clinical Medicine, 2020, Volume 7, Issue 4, Pages 1495-1498

Sjogren’s syndrome (SS) is an autoimmune disorder which is responsible for glandular dysfunction most preferably salivary and lacrimal glands, caused mainly by the lymphocytic infiltration of exocrine glands. It can be classified into two, namely Primary Sjogren’s syndrome and Secondary Sjogren’s syndrome. Primary Sjogren’s syndrome (pSS) occurs in the absence of other autoimmune diseases and is characterised by keratoconjunctiva sicca (dry eyes) and xerostomia (dry mouth), collectively called the sicca syndrome. On the other hand, secondary Sjogren’s syndrome is associated with other autoimmune diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). The prevalence of SS is estimated to be approximately 3% in subjects 50 years or older, with a female to male ratio of 9:1. Conditions associated with SS include rheumatoid arthritis, lupus erythematosus and scleroderma. The clinical manifestations are often vague and mistakenly interpreted and attributed to other medical conditions or iatrogenic disorders. As such, incorrect diagnosis of SS is common and approximately half of all patients are thought to be undiagnosed